In lapatinib-resistant breast cancer cells, HER2 inhibition decreases glycolysis and TCA cycle activity (Supplementary Fig. 5), but decreased flux through these metabolic pathways alone is insufficient to significantly impact cell survival. Here, ERBB2 is linked to breast cancer.